# NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

> **NCT03396601** · PHASE3 · UNKNOWN · sponsor: **NeuroRx, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Bipolar Depression
- Suicidal Ideation

## Interventions

- **DRUG:** Ketamine Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03396601
- **Lead sponsor:** NeuroRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03396601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03396601, "NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03396601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*